8th Apr 2026 00:06
Oslo, 8 April 2026: Circio Holding ASA (the “Companyâ€) hereby announces its preliminary and unaudited financial highlights and an overview of key events for the second half of 2025, as well as certain post-period events year-to-date 2026.
Key highlights and events include:
Up to 40-fold enhanced AAV expression in heart tissue in vivo (circVec generation 3.2), with circVec generation 4 achieving a further 50% boost over generation 3.2New in vivo data post-period showing up to 50-fold enhanced circVec-AAV gene expression in eyeFully funded feasibility study on circVec AAV gene therapy entered with a top 5 global pharmaceutical corporationNew research collaborations established with The University of Texas Medical Branch (infectious diseases) and United Immunity Co. (in vivo CAR-Macrophage therapy)Rights issue completed in Q1 2026 with more than 50% over-subscription, raising total gross proceeds of approximately NOK 68.6 millionNet cash balance as of 31 March 2026 of NOK 42 millionAbstract selected for oral presentation at the ASGCT annual meeting in Boston, May 2026More detailed information about key events and developments, as well as preliminary and unaudited financial information, including the Group's profit and loss for 2H2025 and net cash position as of 31 December 2025, and a going concern assessment can be found in the attached presentation.
The Annual Report for 2025 will be published on 15 April 2026.
For further information, please contact:Erik Digman Wiklund, CEOPhone: +47 413 33 536Email: [email protected]
Lubor Gaal, CFOPhone: +34 683 34 3811Email: [email protected]
About CircioBuilding circular RNA expression systems for enhanced gene and cell therapies
Circio Holding ASA is a biotechnology company developing novel circular RNA expression technology for gene and cell therapy.
Circio has established a unique circular RNA (circRNA) vector expression technology for next generation RNA, DNA and viral therapeutics. The proprietary circVec platform is based on a modular genetic construct designed for efficient biogenesis of multifunctional circRNA inside target cells. The circVec platform has applications in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. It has demonstrated 75-fold increased RNA half-life and up to 40-fold enhanced protein expression vs. conventional mRNA-based viral and non-viral vector systems, with the potential to become a new gold-standard gene expression technology. The circVec R&D activities are being conducted by the wholly owned subsidiary Circio AB in Stockholm, Sweden.
AttachmentsKey Events And Financial Highlights â€" 2H 2025 And YTD 2026
Related Shares:
Circio Ord